ClinicalTrials.gg
RecruitingNCT05585983INVITEDUpdated Oct 28, 2026

INfluenza VaccInation To Mitigate typE 1 Diabetes

A Phase 4 interventional study of Vaxigrip Tetra Sanofi Pasteur Europe in Diabetes Mellitus, Type 1, sponsored by Aarhus University Hospital. Recruiting at 10 sites in Denmark. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Aarhus University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.

Planned enrollment
46th of 157
100 · median 40
Started
2022
with 6 others
Phase 4
19 of 196
2 open now
Primary completion
2027-05
later than 17 of 34 live
Registered
154th of 196
by date

Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 46th largest by planned enrollment of the 157 interventional ones that give a count, is one of 7 that started in 2022, is one of 19 in phase 4, reaches primary completion later than 17 of the 34 other live ones, and was the 154th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, or all of them as a file.
02

Study summary

In a multicenter, prospective, randomized, controlled clinical trial to compare influenza vaccination and placebo in sustaining β cell function in early type 1 diabetes mellitus.

Read the detailed description

Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the insulin-producing β cells in the pancreatic islets. In theory, immunotherapies aimed at re-programming the immune system to avoid β cell destruction is a promising strategy to prevent T1D or delay onset of overt disease.

In this trial we test the hypothesis that influenza vaccination is superior to no influenza vaccination in sustaining β cell function in early T1D. Secondary outcome measures include change in autoantibodies directed against antigens present in the pancreatic islets, measures of severity of disease, change in inflammatory markers, and antibody titers against the four viruses included in the vaccine.

Despite improvements in care, T1D is a leading cause of debilitating complications and early death globally. Children with residual β cell function are at lower risk for severe hypoglycemia, have better diabetes regulation, and have lower insulin requirements compared to children without residual β cell function. Thus, a simple, cheap treatment to mitigate T1D is highly warranted.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients hospitalized with newly diagnosed type 1 diabetes mellitus.
  • Written (parents, legal guardian).

Exclusion criteria

Exclusion Criteria:

  • Influenza vaccination during the current influenza season.
  • Strong indication for influenza vaccination for non-diabetic disease.
  • Severe allergy to eggs or previous allergic reaction to influenza vaccine.
  • Suspicion of febrile illness or acute, ongoing infection.
  • to the active substances or ingredients of Vaxigrip Tetra or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol.
  • Patients with endogenic or iatrogenic that may result in reduced immunization response.
  • Inability to provide from a parent or legal guardian.
  • Age \<7 or ≥18 years.
  • Previous randomization in the INVITED trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Influenza vaccination

    Influenza vaccine, 0.5 mL.

    Biological: Vaxigrip Tetra Sanofi Pasteur Europe

  • Placebo comparator
    Placebo

    Placebo, 0.5 mL saline.

    Biological: Vaxigrip Tetra Sanofi Pasteur Europe

Interventions

  • BiologicalVaxigrip Tetra Sanofi Pasteur Europe

    We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.

06

What researchers measure

Primary outcomes

  1. Change in fasting residual β cell (C-peptide) function.

    Measured as the area under the concentration-time curve (AUC) for mixed-meal tolerance test-stimulated C-peptide concentration over 4 hours relative to baseline (AUC 0-4 h, C-peptide, 12 months/ AUC 0-4 h, C-peptide, baseline)

    Time frame: 12 months

Secondary outcomes

  1. Change in fasting residual β cell (C-peptide) function.

    Measured as the area under the concentration-time curve (AUC) for mixed-meal tolerance test-stimulated C-peptide concentration over 4 hours relative to baseline (AUC 0-4 h, C-peptide, 6 months/ AUC 0-4 h, C-peptide, baseline)

    Time frame: 6 months.

  2. Change in HbA1c

    Measured as standard laboratory test in mmol/mol

    Time frame: 12 months.

  3. Change in insulin requirements.

    Measured as total insulin dose per kg body weight per day as a mean for the last 14 days.

    Time frame: 12 months.

  4. Time-In-Range of blood glucose.

    Defined as percentage time in range (3.9-10.0 mmol/L) of continuous glucose monitoring over 14 days.

    Time frame: 12 months.

  5. Variation of blood glucose.

    Determined as percent coefficient of variation of blood glucose over 14 days.

    Time frame: 12 months.

Other outcomes

  1. Proportion of participants with stimulated C-peptide >0.2 pmol/mL

    Proportion of participants in each of the treatment groups with stimulated C-peptide \>0.2 pmol/mL

    Time frame: 12 months

  2. HbA1c time in range

    Defined as percentage time in range (48mmol/mol or below)

    Time frame: 12 months.

  3. Insulin Dose Adjusted A1c

    Defined as: IDAA1c = HbA1c (%) +4\*total daily insulin dose (IE/kg/24 h)

    Time frame: 12 months

  4. Variation of blood glucose.

    Determined as percent coefficient of variation of blood glucose over 14 days.

    Time frame: 6 months.

  5. Change in GAD 65 antibodies.

    Laboratory method to be determined

    Time frame: 12 months.

  6. Change in GAD 65 antibodies.

    Laboratory method to be determined.

    Time frame: 6 months.

  7. Change in regulatory T cells.

    Defined as percentage change.

    Time frame: 12 months.

  8. Change in insulin autoantibodies.

    Laboratory method to be determined.

    Time frame: 12 months.

  9. Change in zinc transporter-8 autoantibodies

    Laboratory method to be determined.

    Time frame: 12 months.

  10. Change in islet cell autoantibodies.

    Laboratory method to be determined.

    Time frame: 12 months.

  11. Change in cytokine levels.

    Markers to be determined: IL2, IL6, IL8, IL10, TNFα. Laboratory method to be determined.

    Time frame: 12 months.

  12. Change in cytokine levels.

    Markers to be determined: IL2, IL6, IL8, IL10, TNFα. Laboratory method to be determined.

    Time frame: 6 months.

  13. Unplanned hospitalizations.

    Number of unplanned hospitalizations with reasons for hospitalizations.

    Time frame: 12 months.

  14. Serum hemagglutinin inhibition antibody titers against the four viruses included in the vaccine

    Antibody titers.

    Time frame: 12 months.

  15. Serum hemagglutinin inhibition antibody titers against the four viruses included in the vaccine

    Antibody titers.

    Time frame: 6 months.

  16. Clnical endpoints.

    Hospitalizations and unplanned hospital contacts.

    Time frame: Up to 5 years.

  17. Treatment-emergent hypoglycemic events (safety outcome)

    Hypoglycemic events reported according to the American Diabetes Association classification

    Time frame: Up to 12 months.

  18. Treatment-emergent events of diabetic ketoacidosis (safety outcome)

    Events of diabetic ketoacidosis.

    Time frame: Up to 12 months.

07

Study locations

10 of 10 sites recruiting
08

References and documents

Publications

  • Pedersen IB, Kjolby M, Hjelholt AJ, Madsen M, Christensen AR, Adolfsen D, Hjelle JS, Kremke B, Stovring H, Jessen N, Vestergaard ET, Kristensen K, Frobert O. INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes. BMJ Open. 2024 Jul 1;14(6):e084808. doi: 10.1136/bmjopen-2024-084808. PubMed 38950997 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for May 2027, 52 months after the start.

Of 62 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 52 months is above that.

Counting every sponsor, half of 74 studies reached it within 22 months; a quarter within 12 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion May 2026 → May 2027 and completion May 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2022
First posted
Oct 19, 2022
StartActual
Dec 14, 2022
Primary completionEst.
May 1, 2027was May 2026
CompletionEst.
May 1, 2028was May 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 1, 2026→May 1, 2027
Oct 28, 2026
Study completion
May 1, 2027→May 1, 2028
Oct 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38950997 ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38950997 ↗
    Primary completion May 1, 2026→May 1, 2027
    Study completion May 1, 2027→May 1, 2028
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05585983
Responsible party
Ole Frøbert, MD, PhD (Professor, Aarhus University Hospital) — Principal investigator
First posted
Oct 19, 2022
Start date
Dec 14, 2022
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Ole Frøbert, MD, PhD
Contact
olefro@clin.au.dk
0046730895413
Mads F. Kjølby, MD, PhD
Contact
mads@dandrite.au.dk
004560866653

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion